Şunu aradınız:: gastrointestinal (Maltaca - İngilizce)

disturbi gastrointestinal
gastrointestinal disorders

disturbi gastrointestinal i
gastrointestinal disorders

perforazzjoni gastrointestinali (gi - gastrointestinal)
gastrointestinal (gi) perforation

perforazzjonijiet gastro-intestinali (gi - gastrointestinal) u fistuli (ara sezzjoni 4.8)
gastrointestinal (gi) perforations and fistulae (see section 4.8)

perforazzjonijiet gastrointestinali (gi – gastrointestinal) u fistuli serji, xi kultant fatali, ġew osservati b’cabozantinib.
serious gastrointestinal (gi) perforations and fistulas, sometimes fatal, have been observed with cabozantinib.

perforazzjoni gastrointestinali (gi - gastrointestinal) ġiet irrappurtata fi provi kliniċi b’siltuximab għalkemm mhux fil-provi mcd.
gastrointestinal (gi) perforation has been reported in siltuximab clinical trials although not in mcd trials.

gastrointestinal stromal tumours). • pazjenti adulti b’ dermatofibrosarkoma protuberans li ma tkunx tista ’ titneħħa b’ operazzjoni (dfsp) u pazjenti adulti b’ dfsp li tkun reġgħet ħarġet jew/ u li tkun metastatika li ma jkunux jistgħu jiġu operati.
glivec is also indicated for the treatment of • adult patients with kit (cd 117) positive unresectable and/ or metastatic malignant gastrointestinal stromal tumours (gist). • adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/ or metastatic dfsp who are not eligible for surgery.